

# Mark Kirschbaum

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11412641/publications.pdf>

Version: 2024-02-01

28  
papers

1,104  
citations

759233

12  
h-index

677142

22  
g-index

28  
all docs

28  
docs citations

28  
times ranked

2013  
citing authors

#	ARTICLE	IF	CITATIONS
1	Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia. <i>Clinical Cancer Research</i> , 2016, 22, 868-876.	7.0	262
2	A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. <i>Haematologica</i> , 2015, 100, 357-362.	3.5	66
3	A phase I clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2014, 167, 185-193.	2.5	115
4	Results of the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist, in Acute Leukemia. <i>Blood</i> , 2012, 120, 675-675.	1.4	12
5	Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1198-1203.	1.6	195
6	A Multi-Center, Open-Label, Phase I Study of Single Agent RG7112, A First In Class p53-MDM2 Antagonist, In Patients with Relapsed/Refractory Acute Myeloid and Lymphoid Leukemias (AML/ALL) and Refractory Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphomas (CLL/SCLL). <i>Blood</i> , 2010, 116, 657-657.	1.4	16
7	A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma. <i>Blood</i> , 2010, 116, 3957-3957.	1.4	2
8	Comeback for the camptothecins?. <i>Leukemia and Lymphoma</i> , 2009, 50, 1914-1915.	1.3	0
9	Final Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).. <i>Blood</i> , 2009, 114, 1657-1657.	1.4	12
10	Safety and Tolerability of Conatumumab in Combination with Bortezomib or Vorinostat in Patients with Relapsed or Refractory Lymphoma.. <i>Blood</i> , 2009, 114, 1708-1708.	1.4	3
11	Vorinostat in Combination with Decitabine for the Treatment of Relapsed or Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS): A Phase I, Dose-Escalation Study.. <i>Blood</i> , 2009, 114, 2089-2089.	1.4	12
12	Phase I Study of Bortezomib in Combination with Gemcitabine in Relapsed/Refractory Intermediate Grade B-Cell and Mantle Cell Non-Hodgkin's Lymphoma.. <i>Blood</i> , 2009, 114, 1682-1682.	1.4	0
13	Combination Therapy with the Histone Deacetylase Inhibitor Vorinostat Plus the Novel Aurora Kinase A Inhibitor MK-5108 Leads to Enhanced Lymphoma Cell Death Due to Acetylation of p53 and Repression of c-Myc, hTERT, and miRNA Levels.. <i>Blood</i> , 2009, 114, 1690-1690.	1.4	0
14	Novel SIRT1 Agonists, SRT501 and SRT2183, Induce Expression of DNA Repair Genes and Apoptosis of Ph $\beta$ Acute Lymphoblastic Leukemia Cells Alone and in Combination with the HDAC Inhibitor LBH589... <i>Blood</i> , 2009, 114, 3083-3083.	1.4	0
15	HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 4796-4801.	7.1	90
16	hENT1 and Hodgkin lymphoma: Not just crossing the channel. <i>Leukemia and Lymphoma</i> , 2008, 49, 1024-1025.	1.3	1
17	The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph $\beta$ acute lymphoblastic leukemia cells. <i>Blood</i> , 2008, 111, 5093-5100.	1.4	134
18	A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma. A California Cancer Consortium Study.. <i>Blood</i> , 2008, 112, 1564-1564.	1.4	5

#	ARTICLE	IF	CITATIONS
19	Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).. Blood, 2008, 112, 1567-1567.	1.4	12
20	Final Clinical Results of a Phase 2 NCI Multicenter Study of Romidepsin in Recurrent Cutaneous T-Cell Lymphoma (Molecular Analyses Included).. Blood, 2008, 112, 1568-1568.	1.4	10
21	Phase I Study of Vorinostat in Combination with Decitabine in Patients with Relapsed or Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. Blood, 2008, 112, 3651-3651.	1.4	6
22	Combination Therapy with Histone Deacetylase Inhibitor Vorinostat Plus Aurora Kinase Inhibitor MK-0457 Leads to Enhanced Lymphoma Cell Killing with Stabilization of p53 and Repression of C-Myc, hTERT, and Myc-Responsive miRNAs. Blood, 2008, 112, 3628-3628.	1.4	0
23	Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood, 2007, 109, 905-909.	1.4	116
24	A sequential treatment of depsipeptide followed by 5-azacytidine enhances Gadd45beta expression in hepatocellular carcinoma cells. Anticancer Research, 2007, 27, 3783-9.	1.1	12
25	Combination of the Histone Deacetylase Inhibitor Vorinostat and Dasatinib Increases Apoptosis in Bcr-abl+ Cells and Reverses Changes Associated with CML Progression.. Blood, 2006, 108, 2165-2165.	1.4	19
26	A Phase I Study of the Farnesyltransferase Inhibitor Tipifarnib in a Week- on Week-Off Dose Schedule in Acute Myelogenous Leukemia.. Blood, 2006, 108, 1948-1948.	1.4	2
27	Risk Adapted BEACOPP Regimen Based on Early Scintigraphy Can Reduce the Cumulative Dose of Chemotherapy for Standard and High Risk Hodgkin Lymphoma (HD) with No Impairment of Outcome.. Blood, 2005, 106, 815-815.	1.4	0
28	Peripheral Blood Stem Cells vs Bone Marrow for Matched Sibling Transplant in AML and ALL in First Remission.. Blood, 2004, 104, 3321-3321.	1.4	2